{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:20:43Z","timestamp":1787239243073,"version":"build-2736575974"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-023-01743-4","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:01:45Z","timestamp":1692705705000},"page":"171-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin\u2013angiotensin\u2013aldosterone system inhibitors: a retrospective observational study"],"prefix":"10.1093","volume":"37","author":[{"given":"Wakana","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5203-2974","authenticated-orcid":false,"given":"Shun","family":"Minatoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehisa","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijo","family":"Inaguma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotake","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"1743_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL et al (2016) Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis. PLoS ONE 11:e0158765","journal-title":"PLoS ONE"},{"key":"1743_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1053\/j.ajkd.2013.03.009","volume":"62","author":"ME Grams","year":"2013","unstructured":"Grams ME, Chow EKH, Segev DL, Coresh J (2013) Lifetime incidence of CKD stages 3\u20135 in the United States. Am J Kidney Dis 62:245\u2013252","journal-title":"Am J Kidney Dis"},{"key":"1743_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 3:1\u2013150","journal-title":"Kidney Int Suppl"},{"key":"1743_CR4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"1743_CR5","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V et al (2016) Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 67:728\u2013741","journal-title":"Am J Kidney Dis"},{"key":"1743_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41440-018-0116-3","volume":"42","author":"E Mishima","year":"2019","unstructured":"Mishima E, Haruna Y, Arima H (2019) Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials. Hypertens Res 42:469\u2013482","journal-title":"Hypertens Res"},{"key":"1743_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/ki.1983.208","volume":"24","author":"GO Perez","year":"1983","unstructured":"Perez GO, Pelleya R, Oster JR et al (1983) Blunted kaliuresis after an acute potassium load in patients with chronic renal failure. Kidney Int 24:656\u2013662","journal-title":"Kidney Int"},{"key":"1743_CR8","doi-asserted-by":"publisher","first-page":"e005428","DOI":"10.1161\/JAHA.116.005428","volume":"6","author":"G Bandak","year":"2017","unstructured":"Bandak G, Sang Y, Gasparini A et al (2017) Hyperkalemia after initiating renin\u2013angiotensin system blockade: the stockholm creatinine measurements (SCREAM) project. J Am Heart Assoc 6:e005428","journal-title":"J Am Heart Assoc"},{"key":"1743_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1681\/ASN.2008020159","volume":"20","author":"O Moranne","year":"2009","unstructured":"Moranne O, Froissart M, Rossert J et al (2009) Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 20:164\u2013171","journal-title":"J Am Soc Nephrol"},{"key":"1743_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT et al (2015) Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 372:222\u2013231","journal-title":"N Engl J Med"},{"key":"1743_CR11","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P et al (2014) Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312:2223\u20132233","journal-title":"JAMA"},{"key":"1743_CR12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F et al (2015) Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 17:1050\u20131056","journal-title":"Eur J Heart Fail"},{"key":"1743_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ehf2.12561","volume":"7","author":"F Zannad","year":"2020","unstructured":"Zannad F, Hsu B-G, Maeda Y et al (2020) Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC heart failure 7:55\u201365","journal-title":"ESC heart failure"},{"key":"1743_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000504078","volume":"50","author":"SD Roger","year":"2019","unstructured":"Roger SD, Spinowitz BS, Lerma EV et al (2019) Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE. Am J Nephrol 50:473\u2013480","journal-title":"Am J Nephrol"},{"key":"1743_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2215\/CJN.12651018","volume":"14","author":"BS Spinowitz","year":"2019","unstructured":"Spinowitz BS, Fishbane S, Pergola PE et al (2019) Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. Clin J Am Soc Nephrol 14:798\u2013809","journal-title":"Clin J Am Soc Nephrol"},{"key":"1743_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/ndt\/gfaa158","volume":"36","author":"SD Roger","year":"2021","unstructured":"Roger SD, Spinowitz BS, Lerma EV et al (2021) Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials. Nephrol Dial Transplant 36:871\u2013883","journal-title":"Nephrol Dial Transplant"},{"key":"1743_CR17","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1111\/jcpt.13766","volume":"47","author":"AB Huda","year":"2022","unstructured":"Huda AB, Langford C, Lake J, Langford N (2022) Hyperkalaemia and potassium binders: Retrospective observational analysis looking at the efficacy and cost effectiveness of calcium polystyrene sulfonate and sodium zirconium cyclosilicate. J Clin Pharm Ther 47:2170\u20132175","journal-title":"J Clin Pharm Ther"},{"key":"1743_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ndt\/gfz285","volume":"36","author":"SD Roger","year":"2021","unstructured":"Roger SD, Lavin PT, Lerma EV et al (2021) Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. Nephrol Dial Transplant 36:137\u2013150","journal-title":"Nephrol Dial Transplant"},{"key":"1743_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012690","volume":"6","author":"KE Mansfield","year":"2016","unstructured":"Mansfield KE, Nitsch D, Smeeth L et al (2016) Prescription of renin\u2013angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. BMJ Open 6:e012690","journal-title":"BMJ Open"},{"key":"1743_CR20","unstructured":"R Core Team (2020) R: A Language and Environment for Statistical Computing"},{"key":"1743_CR21","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J et al (2019) Welcome to the tidyverse. J Open Source Softw 4:1686","journal-title":"J Open Source Softw"},{"key":"1743_CR22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.32614\/RJ-2021-053","volume":"13","author":"DD Sjoberg","year":"2021","unstructured":"Sjoberg DD, Curry M, Lavery JA et al (2021) Reproducible summary tables with the gtsummary package. R J 13:570\u2013580. https:\/\/doi.org\/10.32614\/RJ-2021-053","journal-title":"R J"},{"key":"1743_CR23","doi-asserted-by":"publisher","DOI":"10.1863\/jss.v042.i08","author":"DE Ho","year":"2011","unstructured":"Ho DE, Imai K, King G, Stuart EA (2011) MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. J Stat Softw. https:\/\/doi.org\/10.1863\/jss.v042.i08","journal-title":"J Stat Softw"},{"key":"1743_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2215\/CJN.12990820","volume":"16","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Talarico R, Tangri N et al (2021) Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence. Clin J Am Soc Nephrol 16:365","journal-title":"Clin J Am Soc Nephrol"},{"key":"1743_CR25","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A et al (2022) Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med 387:2021\u20132032","journal-title":"N Engl J Med"},{"key":"1743_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1681\/ASN.2020050682","volume":"32","author":"EL Fu","year":"2021","unstructured":"Fu EL, Evans M, Clase CM et al (2021) Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study. J Am Soc Nephrol 32:424\u2013435","journal-title":"J Am Soc Nephrol"},{"key":"1743_CR27","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","volume":"180","author":"Y Qiao","year":"2020","unstructured":"Qiao Y, Shin J-I, Chen TK et al (2020) Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med 180:718\u2013726","journal-title":"JAMA Intern Med"},{"key":"1743_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","volume":"80","author":"SJ Leon","year":"2022","unstructured":"Leon SJ, Whitlock R, Rigatto C et al (2022) Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study. Am J Kidney Dis 80:164-173.e1","journal-title":"Am J Kidney Dis"},{"key":"1743_CR29","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/ndt\/gfaa300","volume":"36","author":"CP Walther","year":"2020","unstructured":"Walther CP, Winkelmayer WC, Richardson PA et al (2020) Renin\u2013angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transplant 36:1893\u20131899","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01743-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01743-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01743-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:25Z","timestamp":1777564405000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/1\/171\/8306276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["1743"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01743-4","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"6 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.H. and N.T. received lecture fees from AstraZeneca Co., Ltd. The remaining author has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Fujita Medical University\u2019s Ethics Committee (ID: HM22-296) and was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study did not include animal research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"An opt-out approach for Informed consent was used based on the approval of the ethics board because of the retrospective nature of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}